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Conjugation of small molecule drug to lipid-polymer amphiphiles is a powerful strategy to alter the 
pharmacokinetic profile of these molecules by promoting binding to albumin or other serum 
molecules. Incorporation of a responsive linker between the lipid anchor and the polymer chain could 
be of interest to avoid indefinite binding of the conjugates to hydrophobic pockets of serum proteins 
or phospholipid membranes when reaching a target cell or tissue. Here we report on the synthesis of 
pH-sensitive lipid-polymer conjugates by RAFT polymerisation using a RAFT chain transfer agent that 
is equipped with a pH-sensitive ketal bond between a cholesterol moiety and the trithiocarbonate 
RAFT chain transfer group. We demonstrate that in native form these conjugates exhibit high affinity 




Lipid-polymer amphiphiles are attractive drug carriers owing to their ability to dramatically alter the 
pharmacokinetic profile of small molecule drugs. Indeed, whereas the latter exhibit fast systemic 
deposition and renal clearance, lipidation (i.e. conjugation of a lipid motif to the drug molecule of 
interest) induces binding to serum proteins with hydrophobic binding pockets, such as albumin, which 
confers a much longer circulation half-life.1,2 Moreover, intravenous administration of lipid-drug 
conjugate can result in a higher tumor accumulation due to albumin binding and increased 
accumulation of albumin in the cancer milieu. In the context of subcutaneous administration, lipid-
drug conjugates can form a depot for sustained release or – when properly engineered to be 
amphiphilic and well-water soluble – can hijack the lymphatic albumin flow and accumulate in 
lymphoid tissue.3,4 The latter is of particular interest in view of vaccination and immunotherapy as 
recently demonstrated by the Irvine group for semi macromolecular drugs such as oligonucleotides 
and peptides as well as by our group for immune-modulatory small molecule agonists of Toll like 
receptor 7 (TLR7).5,6 In these works, lipid amphiphiles were designed by conjugating a lipid motif to the 
drug molecule through a non-degradable bond. However, for several applications, a system that 
releases the lipid motif upon cellular internalization could be of benefit, as the lipid motif will tend to 
anchor to the endosomal phospholipid membrane and, hence, limit accessibility of the drug to trigger 
a receptor or to be metabolically activated by enzymes.7 
Therefore, the aim of this work is to design degradable lipid-polymer amphiphiles that can be cleaved 
off, between the lipid anchor and the hydrophilic polymer in response to a physiological trigger. For 
this purpose, we made use of a ketal bond which we and others have reported on before to be stable 
over several days at the physiological pH of 7.4 but can degrade over the time course of several hours 
under mild acidic conditions such as those found in endosomal intracellular vesicles. Note that 
effective degradability of drug delivery systems that are equipped with ketal bonds has effectively 
been shown to occur inside living cells both in vitro and in vivo our recent work. 8,9 
Cholesterol conjugates are known for their spontaneous cell membrane anchoring and albumin-
binding properties.10 Hence, cholesterol was chosen in this work as lipid motif and an acid degradable 
cholesterol-functionalized trithiocarbonate chain transfer agents (CTAs) for reversible addition-
fragmentation chain transfer (RAFT) polymerization was synthesized, according to Scheme 1. First, the 
carboxylate group of cholesteryl hemisuccinate could be activated into an activated ester by 
carbodiimide-mediated esterification with pentafluorophenol. Next, diamino ketal was covalently 
attached to the intermediate product (1) via amidation reaction of the activated ester group. Note that 
a large excess of diamino ketal was used to avoid unwanted side products such as the dicholesteryl 
ketal derivate. Finally, the remaining primary amine of intermediate product (2) was reacted with the 
pentafluorophenyl-activated 2-propanoic acid butyl trithiocarbonate (PFP-PABTC) to yield the acid 
sensitive cholesterol-ketal-CTA. As a control we also used an earlier reported CTA where cholesterol 
was directly conjugate to PABTC through an ester linkage which is stable towards mild acidic conditions 
compared to the here introduced ketal.6 These two CTAs will further on be denoted as cholesterol-
ketal-CTA and cholesterol-ester-CTA. Successful synthesis was proven by NMR and mass spectroscopy 
(data shown in Supplementary Information).  
 
 
Scheme 1. Synthesis of cholesterol-ketal-CTA. 
 
The respective functionalised CTAs were used for the synthesis of well-defined amphiphile conjugates 
by RAFT polymerization (Scheme 2; exemplified for the cholesterol-ketal-CTA)11. Hereto, AIBN was 
utilized as radical initiator, N,N-dimethylacrylamide (DMA) as hydrophilic biocompatible monomer and 
a degree of polymerization (DP) of 50 was targeted through the monomer to CTA ratio. Table 1 gives 
an overview of the polymer characterisation. The polymerization was stopped before completion, 
which was reflected by low dispersity values < 1.10, indicating a narrow molecular weight distribution 
as well as high end group fidelity. Consequently, both CTAs provide excellent control over the radical 
polymerization reaction. To allow monitoring of derived polymers with living cells in vitro via 
fluorescence-based methods, we synthesized rhodamine B labelled copolymers by including 
acryloxyethyl thiocarbamoyl rhodamine B (ARho) to the monomer mixture. In addition, to achieve a 
straightforward characterization in solution by diffusion-ordered (DOSY) NMR, we also synthesised a 
non-amphiphilic polymer based on pentafluorophenylacrylate (PFPA) as monomer using the 
cholesterol-ketal-CTA (note that the polymer’s backbone protons can also individually better be 
referenced from cholesterol end group protons). For this polymer we aimed at a higher DP to obtain a 
sufficient decrease in diffusion coefficient between the cholesterol-polymer conjugate and free 
cholesterol in solution. The properties of these polymers are also shown in Table 1 and S1. Note, both 























































polymerisation of acrylates and acrylamides with high control over the polymerisation, this indicating 
that modification did not hamper the versatility of the RAFT CTA. 
 
Scheme 2. Synthesis of cholesterol-polymer conjugates via RAFT polymerisation.  
 
Table 1. Characterization of cholesterol-polymers. 
Monomer CTA M/CTA/AIBN Conversion a 
(%) 







50/1/0.2 40 20 2.59 4.40 c 1.07 c 
DMA Cholesterol-ketal-
CTA 
50/1/0.2 48 24 3.23 4.50 c 1.07 c 
PFPA Cholesterol-ketal-
CTA 
105/1/0.2 67 70 17.52 9.23 d 1.32 d 
a Determined by 1H NMR analysis. b Calculate based on conversion and molecular weight of monomers and CTAs. 
c Determined by SEC in DMAc. d Determined by SEC in THF. 
 
Next, we focussed on assessing the degradability of the acid-sensitive ketal-containing conjugates. Due 
to the ATP-dependent proton pumps, the pH inside endosomes and lysosomes varies from 4.5 to 6.5. 
Therefore, we chose an intermediate pH of 5.5 to investigate ketal degradation12. For comparison, the 
ester-containing conjugate was used due to the stability of ester group at mild acidic pH. Prior to 
testing in buffered aqueous media, cholesterol-ketal-poly(PFPA) was analysed by DOSY NMR in aceton 
(Figure 1). After exposure to an acid trigger in the NMR tube (5µL trifluoroacetic acid), a subtle change 
in diffusion rate of the polymer was observed, compared to the untreated polymer. Importantly, the 
corresponding cholesterol signals could no longer be observed at the same diffusion rates like the 
poly(PFPA) signals but shifted to the level of freely soluble cholesterol. These results indicate successful 


























































Figure 1. 1H and DOSY NMR (400 MHz, Aceton-D6) analysis of the degradation of cholesterol-ketal-poly(PFPA) 
polymer.  
 
Subsequently, the cholesterol-ketal-poly(DMA) conjugates were exposed to acidic conditions. A 
detailed 1H-NMR analysis of the cholesterol-poly(DMA) polymers demonstrated that the respective 
ketal (black arrow, Figure 2) and the ester group are present after RAFT polymerization (Figure S12). 
However, the ester-containing conjugate remains stable upon exposure to acidic media. Only, the 
protons from the ketal moiety disappeared upon exposure to acidic conditions (red arrow), indicating 
successful ketal cleavage at this pH.  
 
 
Figure 2. 1H-NMR analysis: a zoomed region of the most relevant peaks before and after exposure to acidic 
condition.  
 
Using biolayer interferometry (BLI), the binding capacity of the polymers to albumin was investigated. 
To start, streptavidin sensors were loaded with biotinylated bovine serum albumin (biotin-BSA) and 
afterwards dipped into solutions containing different concentrations of the respective polymers. 
Figure 3 demonstrate strong binding of the cholesterol-ketal-poly(DMA) to BSA-coated sensors. By 
contrast, this was not the case for the same polymers after removal of the cholesterol moiety by acid 
treatment. The calculated equilibrium dissociation constant KD of the intact cholesterol-ketal-
poly(DMA) (table 2) was about 4-log lower than the KD of degraded polymer. Curve fitting and 
calculations emphasize the fact that cholesterol moiety is required for the binding onto albumin-
functionalized sensors. 
 
Figure 3. Bio-layer interferometry sensorgrams at different concentrations of cholesterol-ketal-poly(DMA) 
before and after acid-triggered removal of the cholesterol moiety. 
Poly(DMA) peaks Cholesterol peaks
Ketal peaks
Cholesterol-ketal-p(DMA)












































Table 2. Biolayer interferometry experiment: corresponding KD, KD error , and R2 values.  
Sample R2 KD KD error 
Cholesterol-ketal-poly(DMA) 0.9987 1.452 * 10-10 2.525 * 10-10 
Cholesterol-ketal-poly(DMA) + TFA 0.9696 1.757 * 10-6 4.596 * 10-8 
 
Owing to our interest in immune-engineering and the use of amphiphile carriers for targeting immune 
cells in lymphoid tissue, we investigated the interaction between the cholesterol-polymer conjugates 
and DC 2.4 cells (immortalize mouse dendritic cells). The cells were pulsed with fluorescently labelled 
conjugates at 4 °C and 37 °C, followed by washing to remove unbound polymer and the cellular 
association was quantified by flow cytometry. Note that at 4 °C active energy-dependent endocytosis 
is blocked and mere membrane anchoring due to insertion of the cholesterol moiety into the 
phospholipid bilayer cell membrane is expected to occur. 
Flow cytometry analysis (Figure 4) at 4 °C shows that the mean fluorescence intensity of the cells 
treated with fluorescently labelled poly(DMA/ARho) lacking a cholesterol moiety (i.e. obtained by acid-
based hydrolysis of cholesterol-ketal-poly(DMA/ARho) is within the same range as the 
autofluorescence of untreated cells. By contrast, cells pulsed cholesterol-ketal-poly(DMA/ARho) show 
clear cellular association. These findings indicate that a cholesterol-group is required to anchor to the 
cell membrane. Consequently, the ability of the cholesterol moiety to mediate cellular association at 
4 °C is translated into highly efficient cellular uptake of the conjugates at 37 °C. 
 
Figure 4. Flow cytometry analysis of DC 2.4 pulsed at 4 °C and 37 °C with cholesterol-poly(DMA) before and after 
degradation of ketal-moiety (t-test: ****: < 0.0001; ***: <0.001).  
 
Confocal microscopy at 37°C (Figure 5A) provides visual proof that cholesterol-ketal-poly(DMA/ARho) 
conjugates become well internalised by the cell, showing dotted pattern of intracellular fluorescence 
which likely originates from accumulation in endosomal vesicles. By contrast, a much lower extend of 
intracellular fluorescence is observed in case of cells pulsed with poly(DMA/ARho) lacking a cholesterol 
moiety. To provide further proof that cholesterol-ketal-poly(DMA/Rho) can anchor to the phospholipid 
bilayer cell membrane, we pulsed cells with cholesterol-ketal-poly(DNA/Rho) and poly(DMA/Rho) and 
imaged cell uptake in real time by confocal microscopy (Figure 5B). These experiments indicated that 
during cell uptake, cholesterol-ketal-poly(DMA/Rho) effectively anchors to the cell membrane, which 


































































Figure 5. Confocal microscopy experiment on DC 2.4 of fluorescently labelled polymers. (A1) Overnight 
incubation of cholesterol-ketal polymer at 37 °C with nucleus and membrane staining (left: confocal image – 
middle: overlay with DIC channel – right: maximum intensity projection). (A2) Overnight incubation of 
cholesterol-ketal polymer and cholesterol-ester polymer at 37 °C (left: confocal image – middle: overlay with DIC 
channel – right: maximum intensity projection) (B) Realtime live cell imaging of cellular uptake for both polymers.  
 
Summarizing, we have reported in this work on pH-sensitive cholesterol-polymer conjugates that 
release the cholesterol moiety upon exposure to mildly acidic pH. This was accomplished by inserting 
a ketal bond between cholesterol and a chain transfer agent for RAFT polymerization. This was used 
to grow a polymer chain from cholesterol fused via an pH responsive group. NMR analysis gave proof 
of the pH-dependent degradability of the ketal bond in solution. Biolayer interferometry, flow 
cytometry and confocal microscopy provided proof that interaction with albumin or phospholipid cell 
membranes as well as cellular uptake strongly depends on the presence of the cholesterol moiety. 
Hence, we believe that this polymer design could be used for fabrication of drug-conjugates that take 
full advantage of serum protein-binding and cell membrane-binding properties, but release their 
cholesterol anchor in response to mild acidic pH values such as those found in endosomes as well as 
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Materials and Methods 
Materials 
Unless otherwise noted, all chemicals and solvents were obtained from commercial sources. The RAFT-
CTA 2- propanoic acid butyl trithiocarbonate (PABTC), cholesterol-ester-CTA and PFP-PABTC-CTA were 
synthesized according to literature6,13,14. Cholesteryl hemisuccinate was purchased from Sigma Aldrich. 
2,2'-azobis(2-methylpropionitrile) (AIBN) was purified by recrystallization from diethyl ether prior use 
as initiator. The monomer N,N-dimethylacrylamide (DMA) was purified over an inhibitor remover 
column and pentafluorophenyl acrylate (PFPA) was synthesized as reported in literature15. 
Acryloxyethyl thiocarbamoyl rhodamine B (ARho) was obtained from polysciences. DC 2.4 cell line was 
a kind gift from Dr. Kenneth Rock (University of Massachusetts, Boston, US). Cell culture medium and 
supplements were purchased from Life Technologies.   
 
Instrumentation 
All 1H-, 13C-, 19F- and 2D-NMR spectra were recorded on a Bruker 400 MHz FT NMR spectrometer. 
Chemical Shifts (δ) were provided in ppm relative to TMS. Samples were prepared in CDCl3 or CD3OD. 
Their signals were referenced to residual nondeuterated NMR solvent signals. ESI-mass spectrometry 
(ESI-MS) was performed on a Waters LCT Premier XE Time of flight (TOF) equipped with an electrospray 
Ionization and coupled to a Waters Alliance HPLC system. Size exclusion chromatography (SEC) was 
performed on a Shimadzu 20A system in N,N-dimethylacetamide (DMAc) containing 50 mM LiBr or 
tetrahydrofuran (THF) as solvent. The system was equipped with a 20A ISO-pump and a 20A refractive 
index detector (RID). Measurements were recorded at 50 °C with a flow rate of 0.700 mL/min for 
DMAc-SEC. For THF-SEC a flow rate of 1.00 mL/min was applied at room temperature. Calibration of 
the 2 PL 5 µm mixed-D columns was done with poly(methyl methacrylate) standards for DMAc-SEC or 
poly(styrene)standard for THF-SEC, both obtained from Polymer Standard Services (Mainz, Germany). 
All samples were run with toluene as an internal standard and at a concentration of 5 mg/mL. Bio-layer 
interferometry was performed on a FortéBio Octet® RED96 system. For all experiments, streptavidin 
coated sensors were used (Pall FortéBio) together with black flat bottom 96 well plates (Greiner). 
Confocal microscopy images were recorded on a Leica DMI6000 B inverted microscope equipped with 
an oil immersion objective (Leica, 63 x, NA 1.40) and attached to an Andor DSD2 confocal scanner. 
Images were processed using the ImageJ software package. Flow cytometry analysis (FACS) was 




First, a round bottom flask was filled with cholesteryl hemisuccinate (2.0 g, 4.109 mmol), 
pentafluorophenol (832.0 mg, 4.519 mmol) and 4-(dimethylamino)pyridine (50.2 mg, 0.411 mmol). All 
compounds were dissolved in 40 mL anhydrous dichloromethane (DCM) and cooled on ice. 
Subsequently, a solution of N,N’-diisopropylcarbodiimide (699.9 µL, 4.519 mmol) in anhydrous DCM 
was added dropwise to the stirring reaction mixture. After 1 h ice bad was removed and the mixture 
was stirred overnight at room temperature. The mixture was concentrated and purified by column 
chromatography (95:5 hexane: ethyl acetate) (yield 92.5 %). The purified compound intermediate 1 
was characterized by NMR.  
1H-NMR (400 MHz, CDCl3, Figure S1 cholesteryl hemisuccinate) δ (ppm): 5.36 – 5.24 (m, 1H, -C=CH-
CH2-); 4.66 – 4.49 (m, 1H, -(C=O)-O-CH-CH2-C-); 2.68 – 2.48 (m, 4H, -(C=O)-(CH2)2-(C=O)-); 2.25 (d, J = 
7.9 Hz, 2H, -(C=O)-O-CH-CH2-C-); 2.02 – 1.85 (m, 2H, -C=CH-CH2-CH-CH-); 0.95 (s, 3H, -O-CH-(CH2)2-C-
(CH3)-CH-); 0.84 (d, J = 6.5 Hz, 3H, -C5H6-CH-(CH3)-(CH2)3-CH-(CH3)2); 0.80 (dd, J = 6.6, 1.3 Hz, 6H, -C5H6-
CH-(CH3)-(CH2)3-CH-(CH3)2); 0.61 (s, 3H, -C6H7-C-(CH3)-C5H6-). APT 13C NMR (101 MHz, CDCl3, Figure S2 
cholesteryl hemisuccinate) δ (ppm): 177.99 (HO-(C=O)-CH2-); 171.99 (HO-(C=O)-(CH2)2-(C=O)-O-CH-); 
140.00 (-(C=O)-O-CH-CH2-C=CH-); 123.35 (-C=CH-CH2-CH-CH-); 75.22 (-(C=O)-O-CH-CH2-C-); 57.16 – 
56.61 (-C6H7-CH-(CH2)2-CH-CH-(CH3)-(CH2)3-CH-(CH3)2); 50.48 (-O-CH-(CH2)2-C-CH-); 42.78 (-(CH2)2-C-
CH-(CH2)2-C-(CH3)-CH-); 38.48 (-(C=O)-O-CH-CH2-C-); 37.42 (-O-CH-(CH2)2-C-CH-); 36.26 (-C5H6-CH-
(CH3)-CH2-); 32.32 (-C=CH-CH2-CH-); 32.37 (-C=CH-CH2-CH-); 29.70 - 29.39 (HO-(C=O)-CH2-CH2-(C=O)-O-
); 28.48 (-(CH2)3-CH-(CH3)2); 23.27 – 23.04 (-(CH2)3-CH-(CH3)2); 19.78 (-O-CH-(CH2)2-C-(CH3)-CH-); 19.19 
(-C5H6-CH-(CH3)-(CH2)3-CH-(CH3)2); 12.36 (-C6H7-C-(CH3)-C5H6-). 
 
1H NMR (400 MHz, CDCl3, Figure S3 intermediate 1) δ (ppm): 5.41 – 5.33 (m, 1H, -C=CH-CH2-); 4.73 – 
4.59 (m, 1H, -(C=O)-O-CH-CH2-C-); 3.04 – 2.95 (m, 2H, -(C=O)-CH2-CH2-(C=O)-); 2.80 – 2.69 (m, 2H, -
(C=O)-CH2-CH2-(C=O)-); 2.37 – 2.28 (m, 2H, -(C=O)-O-CH-CH2-C-); 2.05 – 1.93 (m, 2H, -C=CH-CH2-CH-CH-
); 1.02 (s, 3H, -O-CH-(CH2)2-C-(CH3)-CH-); 0.91 (d, J = 6.5 Hz, 3H, -C5H6-CH-(CH3)-(CH2)3-CH-(CH3)2); 0.86 
(dd, J = 6.6, 1.4 Hz, 6H, -C5H6-CH-(CH3)-(CH2)3-CH-(CH3)2); 0.68 (s, 3H, -C6H7-C-(CH3)-C5H6-). APT 13C NMR 
(101 MHz, CDCl3, Figure S4 intermediate 1) δ (ppm): 170.84 (-(C=O)-(CH2)2-(C=O)-O-CH-); 168.63 (C6F5-
O-(C=O)-CH2-); 141.35 – 138.89 (C6F5-O-); 138.89 (-(C=O)-O-CH-CH2-C=CH-); 122.92 (-C=CH-CH2-CH-CH-
); 75.00 (-(C=O)-O-CH-CH2-C-); 56.90 – 56.32 (-C6H7-CH-(CH2)2-CH-CH-(CH3)-(CH2)3-CH-(CH3)2); 50.19 (-
O-CH-(CH2)2-C-CH-); 42.51 (-(CH2)2-C-CH-(CH2)2-C-(CH3)-CH-); 38.11 (-(C=O)-O-CH-CH2-C-); 37.12 (-O-
CH-(CH2)2-C-CH-); 34.77 (-C5H6-CH-(CH3)-CH2-); 32.04 (-C=CH-CH2-CH-); 30.83 (-C=CH-CH2-CH-); 28.67 
(C6F5-O-(C=O)-CH2-CH2-(C=O)-O-); 28.37 (C6F5-O-(C=O)-CH2-CH2-(C=O)-O-); 27.00 (-(CH2)3-CH-(CH3)2); 
22.97 – 22.71 (-(CH2)3-CH-(CH3)2); 19.42 (-O-CH-(CH2)2-C-(CH3)-CH-); 18.95 (-C5H6-CH-(CH3)-(CH2)3-CH-
(CH3)2); 12.06 (-C6H7-C-(CH3)-C5H6-). 19F NMR (471 MHz, CDCl3, Figure S5 intermediate 1) δ (ppm): -
152.07 – -153.03 (m, 2F, o-C6F5-); -157.88 (t, J = 22.0 Hz, 1F, p-C6F5-); -162.14 – -162.37 (m, 2F, m-C6F5-
). 
 
Next, 2,2-bis(aminoethoxy)propane (800.0 µL, 5.020 mmol) and triethylamine (TEA) (700.2 µL, 5.020 
mmol) were dissolved in 40 mL anhydrous DCM under inert atmosphere. The mixture was cooled to 
0°C and a solution of the purified compound of step 1 (1.1 g, 1.673 mmol, dissolved in 3 mL anhydrous 
DCM) was added dropwise while vigorously stirring. After overnight stirring, the crude mixture was 
concentrated under reduced pressure and purified by column chromatography (95:5 DCM:methanol + 
0.5% ammonium hydroxide) (yield 80.0%). The product intermediate 2 was analysed by NMR and MS.  
1H NMR (400 MHz, CD3OD, Figure S6 intermediate 2) δ (ppm): 5.41 (d, J = 4.9 Hz, 1H, -C=CH-CH2-); 4.61 
– 4.51 (m, 1H, -(C=O)-O-CH-CH2-C-); 3.56 – 3.47 (m, 4H, H2N-CH2-CH2-O-C-((CH3)2)-O-CH2-CH2-NH-); 
3.37 – 3.34 (m, 2H, H2N-CH2-CH2-O-C-((CH3)2)-O-CH2-CH2-NH-); 2.89 – 2.83 (m, 2H, H2N-CH2-CH2-O-C-
((CH3)2)-O-CH2-CH2-NH-); 2.63 – 2.56 (m, 2H, -NH-(C=O)-CH2-CH2-(C=O)-); 2.53 – 2.46 (m, 2H, -NH-
(C=O)-CH2-CH2-(C=O)-); 2.34 (d, J = 9.0, 3.2 Hz, 2H, -(C=O)-O-CH-CH2-C-); 2.12 – 1.99 (m, 2H, -C=CH-CH2-
CH-CH-); 1.38 (s, 6H, -O-C-((CH3)2)-O-); 1.07 (s, 3H, -O-CH-(CH2)2-C-(CH3)-CH-); 0.97 (d, J = 6.6 Hz, 3H, -
C5H6-CH-(CH3)-(CH2)3-CH-(CH3)2); 0.90 (dd, J = 6.6, 1.5 Hz, 6H, -C5H6-CH-(CH3)-(CH2)3-CH-(CH3)2); 0.75 (s, 
3H, -C6H7-C-(CH3)-C5H6-). APT 13C NMR (101 MHz, CDCl3, Figure S7 intermediate 2) δ (ppm):
 
174.50 (-
NH-(C=O)-(CH2)2-(C=O)-O-CH-); 173.79 (-NH-(C=O)-(CH2)2-(C=O)-O-CH-); 141.14 (-(C=O)-O-CH-CH2-
C=CH-); 123.69 (-C=CH-CH2-CH-CH-); 101.48 (NH2-(CH2)2-O-C-((CH3)2)-O-CH2-); 75.71 (-(C=O)-O-CH-CH2-
C-); 62.04 – 60.63 (NH2-CH2-CH2-O-C-((CH3)2)-O-CH2-CH2-NH-); 58.14 – 57.57 (-C6H7-CH-(CH2)2-CH-CH-
(CH3)-(CH2)3-CH-(CH3)2); 51.64 (-O-CH-(CH2)2-C-CH-); 43.53 (-(CH2)2-C-CH-(CH2)2-C-(CH3)-CH-); 42.19 
(NH2-CH2-CH2-O-); 41.13 (NH2-(CH2)2-O-C-((CH3)2)-O-CH2-CH2-NH-); 39.12 (-(C=O)-O-CH-CH2-C-); 37.77 
(-O-CH-(CH2)2-C-CH-); 33.02 (-C=CH-CH2-CH-CH-); 31.36 (-NH-(C=O)-CH2-CH2-(C=O)-O-); 30.64 (-NH-
(C=O)-CH2-CH2-(C=O)-O-); 25.15 (NH2-(CH2)2-O-C-((CH3)2)-O-CH2-CH2-NH-); 23.21 – 22.96 (-C5H6-CH-
(CH3)-(CH2)3-CH-(CH3)2); 19.77 (-O-CH-(CH2)2-C-(CH3)-CH-); 19.28 (-C5H6-CH-(CH3)-(CH2)3-CH-(CH3)2); 
12.34 (-C6H7-C-(CH3)-C5H6-). 
ESI-MS (Figure S8) : m/z [M+H]+ = 631.5073 (theoretical); found = 631.4977 
[M+Na]+ = 653.4892 (theoretical); found = 653.4891 
[M+K]+ = 669.4632 (theoretical); found = 669.4615 
 
Finally, PFP-PABTC (1.6 g, 3.900 mmol) was dissolved in anhydrous DCM (9 mL) into a round bottom 
flask and placed under inert atmosphere on ice. To this vigorously stirred solution, a mixture of the 
obtained intermediate 2 (0.82 g, 1.300 mmol) and TEA (543.4 µL, 3.900 mmol) in 2 mL dry DCM was 
added dropwise. Afterwards, the solution was placed at room temperature and left stirring overnight. 
The synthesized product was purified by column chromatography using a gradient (from 70:30 hexane: 
EtOAc + 1% TEA to 50:50 hexane: EtOAc + 1% TEA) (yield 90%). The product cholesterol-ketal-CTA was 
analysed by NMR and MS. 
1H NMR (400 MHz, CD3OD, Figure S9 Cholesterol-ketal-CTA) δ (ppm): 5.41 – 5.36 (m, 1H, -C=CH-CH2-); 
4.59 – 4.49 (m, 1H, -(C=O)-O-CH-CH2-C-); 3.50 – 3.33 (m, 8H, -(C=O)-NH-(CH2)2-O-C-((CH3)2)-O-(CH2)2-
NH-(C=O)-); 2.61 – 2.55 (m, 2H, -NH-(C=O)-CH2-CH2-(C=O)-); 2.52 – 2.45 (m, 2H, -NH-(C=O)-CH2-CH2-
(C=O)-); 2.35 – 2.29 (m, 2H, -(C=O)-O-CH-CH2-C-); 2.11 – 2.00 (m, 2H, -C=CH-CH2-CH-CH-); 1.56 – 1.54 
(d, J = 7.33 Hz, 3H, -S-CH-(CH3)-(C=O)-); 1.34 – 1.32 (m, 6H, -O-C-((CH3)2)-O-); 1.05 (s, 3H, -O-CH-(CH2)2-
C-(CH3)-CH-); 0.97 – 0.93 (m, 6H, -C5H6-CH-(CH3)-(CH2)3-CH-(CH3)2 + CH3-((CH2)3)-S-); 0.88 (dd, J = 6.6, 
1.5 Hz, 6H, -C5H6-CH-(CH3)-(CH2)3-CH-(CH3)2); 0.72 (s, 3H, -C6H7-C-(CH3)-C5H6-). APT 13C NMR (101 MHz, 
CDCl3, Figure S10 Cholesterol-ketal-CTA) δ (ppm): 174.39 (-NH-(C=O)-(CH2)2-(C=O)-O-CH-); 173.81 (-
NH-(C=O)-(CH2)2-(C=O)-O-CH-); 173.00 (-S-CH-(CH3)-(C=O)-NH-); 141.02 (-(C=O)-O-CH-CH2-C=CH-); 
123.64 (-C=CH-CH2-CH-CH-); 101.34 (NH2-(CH2)2-O-C-((CH3)2)-O-CH2-); 75.61 (-(C=O)-O-CH-CH2-C-); 
60.63 – 60.22 (-NH-CH2-CH2-O-C-((CH3)2)-O-CH2-CH2-NH-); 58.05 – 57.53 (C6H7-CH-(CH2)2-CH-CH-(CH3)-
CH2-); 51.55 (-O-CH-(CH2)2-C-CH-); 50.59 (-S-CH-(CH3)-(C=0)-); 38.23 (-O-CH-CH2-C-); 37.05 (-C5H6-CH-
(CH3)-); 33.19 (-C=CH-CH2-CH-); 33.01 (-C=CH-CH2-CH-); 31.38 (-NH-(C=O)-CH2-CH2-(C=O)-O-); 31.27 (-
NH-(C=O)-CH2-CH2-(C=O)-O-); 29.14 (-(CH2)3-CH-(CH3)2); 25.29 (-NH-(CH2)2-O-C-((CH3)2)-O-CH2-CH2-NH-
); 23.04 – 22.94 (-C5H6-CH-(CH3)-(CH2)3-CH-(CH3)2); 19.80 (-O-CH-(CH2)2-C-(CH3)-CH-); 19.25 (-C5H6-CH-
(CH3)-(CH2)3-CH-(CH3)2); 17.90 (-S-CH-(CH3)-(C=O)-); 13.93 (CH3-(CH2)3-S-); 12.33 (-C6H7-C-(CH3)-C5H6-).  
ESI-MS (Figure S11) : m/z [M+H]+ = 851.5073 (theoretical); found = 851.5098 
[M+Na]+ = 873.4892 (theoretical); found = 873.4922 
[M+K]+ = 889.4632 (theoretical); found = 889.4661 
 
RAFT polymerization 
The purified monomer DMA (113.0 mg, 1.14 mmol), cholesterol-ketal-CTA (19.4 mg, 0.023 mmol) and 
initiator AIBN (0.75 mg, 0.005 mmol) were dissolved in 0.5 mL anhydrous N,N-dimethylformamide 
(DMF) in a Schlenk tube equipped with a stir bar. The solution was degassed by five freeze-vacuum-
thaw cycles and afterwards the Schlenk tube was placed in a preheated oil bath of 70 °C. After 2 h, the 
polymerization was stopped and the polymer was purified by threefold precipitation in ice cold diethyl 
ether. The polymer was dried under vacuum. Monomer conversion was calculated by 1H-NMR of the 
reaction mixture and the polymer was further characterized by size exclusion chromatography (SEC) 
using N,N-dimethylacetamide (DMAc) as eluent and NMR spectroscopy. Similar conditions were 
applied for the polymerization of cholesterol-ester-poly(DMA) and cholesterol-ketal-poly(PFPA). The 
latter polymer was purified by precipitation in ice cold ethanol. 
In addition to poly(DMA), a fluorescently labelled derivative polymer was synthesized by 
copolymerization of DMA with the fluorescent monomer acryloxyethyl thiocarbamoyl rhodamine B 
(ARho). A DMA:ARho:CTA molar ratio of 49.5:0.05:1 was applied with identical polymerization 
conditions as described above. 












50/0.05/1/0.2 85 43 4.87 5611 1.08 
Cholesterol-ketal-
CTA 
50/0.05/1/0.2 92 46 5.41 5560 1.07 
a Determined by 1H NMR analysis. b Calculate based on conversion and molecular weight of monomers and CTAs. 
c Determined by SEC in DMAc.  
 
Acid-triggered cholesterol removal 
Solutions at 5 mg/mL for the fluorescently labelled polymers were prepared in acetate buffer (pH= 5.5, 
0.1 M) and stirred overnight at room temperature. Afterwards, the samples were dialysed against 
water and  freeze dried. The products could then be analysed by 1H-NMR and will further used for in 
vitro cell experiments.  
 
Biolayer interferometry  
Bovine serum albumin (BSA) was biotinylated by standard NHS-activated ester chemistry and dilution 
series (1, 2.5, 5 and 50 µg/mL) of the polymer were prepared in PBS. All solutions were transferred 
into black flat bottom 96 well plate which was then placed into an Octed Red96 system (Pall FortéBio). 
First, the streptavidin sensors were washed and a baseline in PBS was recorded for 60 s. Then, the 
sensors were loaded with BSA-biotin by dipping into 12.5 nM biotine-BSA (66.5 kDa) solution for 300 
s. After an additional wash and baseline step, the coated sensors were dipped into the polymer 
solutions for 600 s to measure absorption. Next, the sensors were immersed in PBS for 600 s to 
measure desorption. The obtained curves were fitted and calculation of KD values was done by the 
FortéBio software package.  
 
In vitro cell experiments 
Dendritic cells 2.4 (DC 2.4) were cultured in RMPI medium, supplemented with 10 % fetal bovine serum 
(FBS), antibiotics (50 units/ml penicillin and 50 µg/ml streptomycin), 2 mM L-glutamine and 1 mM 
sodium pyruvate. Cells were incubated at 37 °C in a controlled and sterile environment of 95 % relative 
humidity and 5 % CO2. Dendritic cells were used for all cell experiments.  
 
Confocal microscopy 
DC 2.4 cells were plated on a Willco-Dish glass bottom dishes (15 000 cells, suspended in 180 µL of 
culture medium) and incubated overnight. 20 µL of polymer solution (1 mg/mL) was added to the cells 
and cells were further incubated overnight. Subsequently, the culture medium was removed and the 
cells were washed with PBS and fixated in 4 % paraformaldehyde. After 15 min at 37 °C, cells were 
washed and 250 µL of a staining solution was added. After 30 min, the supernatants were removed 
and the dishes were washed with PBS prior to imaging. The staining solution (in total 1 mL PBS) was 
supplemented with 10 µL Hoechst stock solution (1 mg/mL in DMSO) and 5 µL of cholera toxin subunit 
(CTB) 488 stock solution (1 mg/mL in PBS). 
 
Flow cytometry 
DC 2.4 cells were seeded in 24-well culture plates (150 000 cells, 450 µL per well) and adhered 
overnight. The cells were placed on ice for 15 minutes and 50 µL of ice cold samples were added and 
incubated for 2 h on ice. Then, cells were washed and 0.5 mL cell dissociation buffer was added for 
detaching. Afterwards, cells were transferred into Eppendorf tubes, centrifugated, resuspended and 
analysed by flow cytometry. The experiment was also executed at 37 °C, whereby the samples were 
incubated overnight at 37°C. The data were analysed by FlowJo software package. 
 
 








































Figure S2. APT 13C-NMR spectrum of cholesteryl hemisuccinate in CDCl3. 
 













































































Figure S4. APT 13C-NMR spectrum of intermediate 1 in CDCl3. 
 

































































































































































Figure S8. ESI-MS of intermediate 2. 
 
























































Figure S10. APT 13C-NMR spectrum of cholesterol-ketal-CTA in CD3OD. 
 
























































































Figure S12. 1H-NMR analysis: a zoomed region of the most relevant peaks before and after exposure 








Cholesterol-ketal-p(DMA) + pH 5.5
Cholesterol-ester-p(DMA) + pH 5.5
